BGMA backs ‘lifecycle adjustment’ levy scheme for branded medicines

The government has proposed a ‘lifecycle adjustment’ mechanism, which would levy different rates on branded medicines sold to the NHS, dependent on their age and competition in the market.
medicines on shelves
The current levy for branded medicines is 27.5%, which was introduced in April 2023

DR P. MARAZZI/SCIENCE PHOTO LIBRARY

The British Generic Manufacturers Association (BGMA), has backed the concept of a ‘lifecycle adjustment’ (LCA) to levies charged by the government, which have been proposed as part of an overhaul of the statutory scheme for branded medicines pricing.

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Last updated